Igm Biosciences Stock Piotroski F Score
| IGMS Stock | USD 9.09 0.15 1.62% |
IGM | Piotroski F Score |
At this time, it appears that IGM Biosciences' Piotroski F Score is Poor. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
4.0
Piotroski F Score - Poor
| Current Return On Assets | Negative |
| Change in Return on Assets | Decreased |
| Cash Flow Return on Assets | Negative |
| Current Quality of Earnings (accrual) | Improving |
| Asset Turnover Growth | Decrease |
| Current Ratio Change | Increase |
| Long Term Debt Over Assets Change | N/A |
| Change In Outstending Shares | Decrease |
| Change in Gross Margin | No Change |
IGM Biosciences Piotroski F Score Drivers
The critical factor to consider when applying the Piotroski F Score to IGM Biosciences is to make sure IGM is not a subject of accounting manipulations and runs a healthy internal audit department. So, if IGM Biosciences' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if IGM Biosciences' financial numbers are properly reported.
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0028 | 0.005 |
|
| |||||
| Total Current Liabilities | 23.7 M | 42.5 M |
|
| |||||
| Non Current Liabilities Total | 186.6 M | 177.7 M |
|
| |||||
| Total Assets | 300.2 M | 423.4 M |
|
| |||||
| Total Current Assets | 256.8 M | 347.6 M |
|
|
IGM Biosciences F Score Driver Matrix
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between IGM Biosciences' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards IGM Biosciences in a much-optimized way.
Click cells to compare fundamentals
About IGM Biosciences Piotroski F Score
F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.Book Value Per Share |
|
IGM Biosciences Current Valuation Drivers
We derive many important indicators used in calculating different scores of IGM Biosciences from analyzing IGM Biosciences' financial statements. These drivers represent accounts that assess IGM Biosciences' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of IGM Biosciences' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 343.3M | 2.7B | 982.0M | 706.7M | 434.7M | 594.6M | |
| Enterprise Value | 322.1M | 2.5B | 877.4M | 626.6M | 362.1M | 536.9M |
IGM Biosciences ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, IGM Biosciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to IGM Biosciences' managers, analysts, and investors.Environmental | Governance | Social |
About IGM Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze IGM Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of IGM Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of IGM Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with IGM Biosciences
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if IGM Biosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in IGM Biosciences will appreciate offsetting losses from the drop in the long position's value.Moving together with IGM Stock
| 0.69 | EGRX | Eagle Pharmaceuticals | PairCorr |
| 0.68 | JNJ | Johnson Johnson Financial Report 18th of July 2024 | PairCorr |
Moving against IGM Stock
| 0.5 | BSGM | Biosig Technologies | PairCorr |
The ability to find closely correlated positions to IGM Biosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace IGM Biosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back IGM Biosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling IGM Biosciences to buy it.
The correlation of IGM Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as IGM Biosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if IGM Biosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for IGM Biosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out IGM Biosciences Altman Z Score, IGM Biosciences Correlation, IGM Biosciences Valuation, as well as analyze IGM Biosciences Alpha and Beta and IGM Biosciences Hype Analysis. For more information on how to buy IGM Stock please use our How to Invest in IGM Biosciences guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Complementary Tools for IGM Stock analysis
When running IGM Biosciences' price analysis, check to measure IGM Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IGM Biosciences is operating at the current time. Most of IGM Biosciences' value examination focuses on studying past and present price action to predict the probability of IGM Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IGM Biosciences' price. Additionally, you may evaluate how the addition of IGM Biosciences to your portfolios can decrease your overall portfolio volatility.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |
Is IGM Biosciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of IGM Biosciences. If investors know IGM will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about IGM Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.06) | Revenue Per Share 0.037 | Quarterly Revenue Growth (0.05) | Return On Assets (0.38) | Return On Equity (1.18) |
The market value of IGM Biosciences is measured differently than its book value, which is the value of IGM that is recorded on the company's balance sheet. Investors also form their own opinion of IGM Biosciences' value that differs from its market value or its book value, called intrinsic value, which is IGM Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because IGM Biosciences' market value can be influenced by many factors that don't directly affect IGM Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between IGM Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if IGM Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, IGM Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.